Drug Approval | September 01, 2021
Zymo Research receives CE Mark for new Covid-19 SafeCollect kits
Self-collection devices designed for ease of use and safety
Self-collection devices designed for ease of use and safety
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
XELJANZ is the first and only Janus kinase (JAK) inhibitor approved in Europe for the treatment of polyarticular JIA and juvenile PsA and has received regulatory approval in four indications in the European Union, the most of any JAK inhibitor
The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
InferVision's AI applications have been developed to quickly and accurately analyse signs of pulmonary infections from regular chest CT images. These images are processed to indicate ground-glass opacity and high tissue density, which are key findings of viral pneumonia caused by the coronavirus
Deal for 100 million doses with additional 100 million through 2023
In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark
Subscribe To Our Newsletter & Stay Updated
